BioCurate and Monash University accelerate research into targeted treatments for triple negative breast cancer

The first award under BioCurate's new "Proof of Concept" fund has been granted to the Monash Biomedicine Discovery Institute (BDI). This award will support the key research needed to determine the effectiveness of targeting two proteins that could lead to novel, targeted treatments for triple negative breast cancer (TNBC) and other poor prognosis cancers. The research, led by Professor Roger Daly, who heads the BDI's cancer program, has already identified two proteins that are required by TNBC cells to grow. These proteins represent potential targets for small molecule drugs that could be used to treat this type of cancer. Triple negative breast cancer represents around 15 percent of breast cancers and is an aggressive form of cancer with limited therapy options. Chemotherapy is the most common treatment, but has detrimental side effects that negatively affect quality of life. "Our aim was to identify new targeted treatments that could avoid the side effects of chemotherapy.